You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 25, 2024

CLINICAL TRIALS PROFILE FOR ONABOTULINUMTOXINA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for onabotulinumtoxina

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00439140 ↗ Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder Terminated Allergan Phase 3 2007-06-01 This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
NCT00777803 ↗ NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines Completed Merz Pharmaceuticals GmbH Phase 3 2008-11-01 NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton). Injected into the muscle, NT201 causes a reversible local relaxation of the injected muscle. Botulinum toxin type A is used for aesthetic treatment of mimic wrinkles and in the therapy of neurologic diseases. This study will investigate the safety and efficacy (non-inferiority) of NT 201 in comparison with OnabotulinumtoxinA (Vistabel®) in the treatment of glabellar frown lines.
NCT00910520 ↗ Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Completed Allergan Phase 3 2009-09-01 The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
NCT00910845 ↗ Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Completed Allergan Phase 3 2009-09-01 The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for onabotulinumtoxina

Condition Name

Condition Name for onabotulinumtoxina
Intervention Trials
Overactive Bladder 14
Glabellar Frown Lines 7
Glabellar Lines 6
Overactive Bladder Syndrome 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for onabotulinumtoxina
Intervention Trials
Urinary Bladder, Overactive 21
Migraine Disorders 16
Urinary Incontinence 11
Enuresis 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for onabotulinumtoxina

Trials by Country

Trials by Country for onabotulinumtoxina
Location Trials
United States 316
Canada 31
United Kingdom 17
Germany 17
France 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for onabotulinumtoxina
Location Trials
California 39
Florida 23
New York 22
Texas 20
Tennessee 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for onabotulinumtoxina

Clinical Trial Phase

Clinical Trial Phase for onabotulinumtoxina
Clinical Trial Phase Trials
Phase 4 36
Phase 3 29
Phase 2/Phase 3 4
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for onabotulinumtoxina
Clinical Trial Phase Trials
Completed 53
Recruiting 25
Not yet recruiting 21
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for onabotulinumtoxina

Sponsor Name

Sponsor Name for onabotulinumtoxina
Sponsor Trials
Allergan 50
Walter Reed National Military Medical Center 4
AbbVie 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for onabotulinumtoxina
Sponsor Trials
Other 105
Industry 65
U.S. Fed 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.